直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Article

Introduction to Intellectual Property: A U.S. Perspective

March 27, 2015

Cold Spring Harbor Perspectives in Medicine

By Thomas Lee Irving; Amanda K. Murphy, Ph.D.; *Stacy D. Lewis

Many biotechnology innovators opt for patents, which grant legal, time-limited monopolies to eligible inventions. To obtain a patent in the United States, an invention must be useful to the public and made or altered by the hand of man. It must then clear the hurdles of novelty and nonobviousness. If an invention can do that, obtaining a patent becomes a matter of form: Who qualifies as an inventor? Does the application demonstrate possession, stake a clear claim to the protection sought, and enable “ordinary” colleagues to replicate it? Has the inventor purposely withheld anything? In this article, Finnegan attorneys Thomas L. Irving, Amanda K. Murphy, and Michael A. Stramiello address each of these hurdles as they apply to biotech inventions.

*Stacy Lewis is a law clerk at Finnegan.

Tags

patent-eligible, claim construction

Related Practices

Prosecution and Portfolio Management

Trade Secrets

Related Industries

Life Sciences

Biotechnology

Related Offices

Washington, DC

Related Professionals

Amanda K. Murphy, Ph.D.
Partner
London
+44 (0)20 7864 2814
Email

Originally printed in Cold Spring Harbor Perspectives in Medicine. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.

Related Insights

Reception

2026 IPO Education Foundation Awards Dinner

December 15, 2026

Washington, DC

Panel Discussion

2026 Advanced Patent Law Institute

December 3-4, 2026

Stanford

Conference

IPBC Asia 2026

November 17-19, 2026

Tokyo

Conference

IAM Live: Trade Secret Strategy USA

November 1, 2026

San Jose

Charitable

2026 ALYN Hospital Wheels of Love Ride

November 8-12, 2026

Northern District

Conference

IAM Live: Navigating the UPC 2026

November 4, 2026

Paris

Conference

Life Sciences Patent Network North America Fall 2026

November 2-3, 2026

San Francisco

Conference

2026 ANA Masters of Advertising Law Conference

November 2-4, 2026

Huntington Beach

Conference

2026 AIPLA Annual Meeting

October 29-31, 2026

Washington, DC

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP